The synthesis and evaluation of caffeine analogues as inhibitors of monoamine oxidase B and antagonists of the adenosine A₂A receptor
MetadataShow full item record
The adenosine A2A receptor has emerged as an attractive target for the treatment of Parkinson's disease (PD). Evidence suggests that antagonists of the A2A receptor (A2A antagonists) partially alleviate the symptoms of PD, prevent the development of motor complications and may also slow the underlying neurodegenerative process. It was recently reported that several members of the (E)-8-styrylcaffeine class of A2A antagonists also are potent inhibitors of monoamine oxidase B (MAO-B).
- Health Sciences